Compounded vs Brand-Name GLP-1s

When people compare “compounded vs brand-name” GLP-1s, they’re usually really asking one question: is the cheaper version just as good? For most of 2023 and 2024 that was a reasonable question, because the price difference was enormous and the FDA’s drug-shortage rules made compounded copies broadly available. In mid-2026 the answer has changed — not because compounded products got worse, but because the two things that made them attractive (a huge price gap and easy access) have both eroded. This page compares the two on the factors that actually matter: what’s in the vial, how they’re regulated, what the evidence covers, how they’re dosed, what they cost now, and who each one realistically suits today.

What “brand” and “compounded” actually mean

A brand-name GLP-1 is an FDA-approved finished drug: semaglutide sold as Ozempic, Wegovy, and Rybelsus (Novo Nordisk), and tirzepatide sold as Mounjaro and Zepbound (Eli Lilly). Each is manufactured to federal current Good Manufacturing Practice (cGMP) standards, tested batch by batch, and dispensed in a pre-filled pen (or, increasingly, an oral tablet) at a known, fixed strength.

A compounded GLP-1 is a version mixed by a pharmacy rather than the original manufacturer. During the 2022-2025 shortage, compounding pharmacies could legally prepare their own semaglutide and tirzepatide using the active ingredient, typically as a liquid in a multi-dose vial that the patient draws up and injects. Crucially, compounded drugs are not FDA-approved and not reviewed by the FDA for safety, effectiveness, or quality. They exist under specific carve-outs in federal law, not under the approval process that the brands go through.

That single regulatory difference is the root of almost every other difference below.

Are they the same drug? Quality and what’s in the vial

If a compounded product uses genuine base-form semaglutide or tirzepatide, the core molecule is the same as the brand. But “same molecule” is not “same product,” and three things commonly diverge:

• Salt forms. The FDA has repeatedly warned that some compounded products used semaglutide sodium or semaglutide acetate rather than the base semaglutide in the approved drugs. The agency treats these salts as different active ingredients that haven’t been shown to be safe or effective, and says it isn’t aware of a lawful basis for using them in compounding. You generally can’t tell from a vial label which form you received.
• Added ingredients. Compounded GLP-1s are often combined with extras such as vitamin B12 or B6, marketed as helping with energy or side effects. These combinations aren’t part of any approved product and haven’t been studied as finished drugs.
• Concentration and consistency. A brand pen delivers a standardized amount every time. A compounded vial’s actual concentration depends on the individual pharmacy’s preparation and isn’t independently verified the way an approved drug’s is. Reputable 503A pharmacies source active ingredient from FDA-registered facilities, but the finished compounded product still isn’t FDA-reviewed.

Note: The FDA has also flagged counterfeit brand pens circulating in the US supply chain. “Brand vs compounded” assumes you’re getting an authentic brand pen from a licensed pharmacy — another reason the source you buy from matters as much as the category.

Efficacy: what the evidence actually covers

The headline weight-loss and diabetes results everyone quotes — the trials behind semaglutide and tirzepatide — were run on the brand-name, FDA-approved formulations. There is no equivalent body of trial evidence for compounded versions as products.

This doesn’t mean compounded semaglutide “doesn’t work.” If it contains true base-form semaglutide at the labeled strength, it should behave like semaglutide. The honest point is narrower: because compounded products aren’t standardized or tested as finished drugs, you can’t assume any given batch matches the brand on strength, purity, or results. With the brand, that consistency is part of what FDA approval and cGMP buy you. With compounding, it depends entirely on the pharmacy.

Safety and the delivery difference

The most consequential safety gap isn’t the molecule — it’s how the dose reaches you.

Brand GLP-1s come in fixed-dose pens (or tablets). You dial or click a set dose; the device controls the amount. Compounded GLP-1s typically come in vials, and the patient measures each dose with a syringe. That hand-off has caused real harm: the FDA has received reports of patients injecting 5 to 20 times the intended dose, driven by confusion between milligrams, milliliters, and “units,” and by inexperience with drawing from a vial. The agency has linked compounded-semaglutide dosing errors to hospitalizations and a number of deaths, and by mid-2025 had logged hundreds of adverse-event reports tied to compounded products.

Some of those adverse events are the familiar GLP-1 side effects (nausea, vomiting, diarrhea, abdominal pain). But the overdose pattern is specific to the vial-and-syringe model and is largely designed out of the brand pens. For a reader weighing the two, this is one of the strongest points in the brand’s favor that has nothing to do with price.

Cost: the gap that’s closing in 2026

This is where the comparison has flipped hardest.

In 2024, the math was stark: compounded semaglutide commonly ran around $150-300/month, while brand Wegovy without insurance was roughly $1,300/month. At that spread, cost alone drove millions of people toward compounded.

In mid-2026, brand list prices are still high on paper — Wegovy lists around $1,349/month, Ozempic and Rybelsus around $1,028, Zepbound near $1,086 — and plain retail cash with no program remains a bad deal at roughly $900-1,600/month. But almost nobody paying attention pays those numbers anymore, because the manufacturers built direct cash-pay channels:

• Wegovy through NovoCare: about $349/month for the standard pen, with an introductory $199/month for the first two fills of the lowest doses; the oral Wegovy pill starts near $149/month.
• Ozempic through NovoCare: roughly $349-499/month self-pay, with the same $199 intro window.
• Zepbound single-dose vials through LillyDirect: roughly $299-449/month by dose.
• With commercial insurance plus a manufacturer savings card, eligible on-label patients can land near $0-25/month — cheaper than any compounded option.

Compounded versions still circulate around $150-500/month. So the price advantage hasn’t vanished, but it’s now often a difference of a hundred dollars or so against an FDA-approved, legal, quality-assured product — not a difference of a thousand. For many people that changes the calculation entirely. (For the full brand breakdowns, see the Wegovy and Zepbound cost pages; for coverage rules, the insurance page.)

Legal status and availability right now

The other pillar that propped up compounded GLP-1s — easy legal access — has also given way.

Compounded copies were broadly legal only while the brands were on the FDA’s drug-shortage list. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, then set wind-down deadlines for pharmacies to stop making copies. In April 2026 the agency went further, proposing to remove semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulk list, signaling that large-scale compounding of these drugs has no regulatory future. Industry lawsuits failed to win injunctions to stop the wind-down.

A narrow 503A patient-specific path can still exist where a licensed prescriber documents a genuine clinical reason a particular patient needs a compounded preparation the commercial product can’t provide. But making what’s essentially a cheap copy of an available approved drug now runs into the “essentially a copy” limits in federal law. The practical upshot: the mass-market compounded lane that defined 2023-2024 is closing, while brand pens are widely stocked and available. We keep the blow-by-blow regulatory timeline on the dedicated legal-status page, and the 503A-vs-503B mechanics on the compounding-infrastructure page.

Which makes sense for whom in mid-2026

Putting it together:

• Brand-name is now the default for most people. It’s FDA-approved, made under federal quality rules, delivered in a dose-controlled pen, and — through manufacturer cash programs or insurance — frequently priced within reach. If you have commercial coverage for the on-label use, it’s also usually the cheapest legitimate route.
• Compounded made sense mainly under shortage conditions — when the brand was unavailable or unaffordable by a wide margin. Both of those conditions have largely reversed. If you’re still on a compounded protocol, it’s worth talking to a prescriber about moving to brand, both for the quality assurance and because compounded access is narrowing.
• The one durable niche for legitimate compounding is genuine, documented clinical customization for an individual patient — not a discount channel. Anything advertised as a cheap “generic Ozempic” or “generic Zepbound” should be treated with suspicion, both legally and on quality.

The short version: in 2026 the brand-vs-compounded decision is no longer “save a fortune by going compounded.” It’s “an FDA-approved, dose-controlled product that’s now affordably priced” versus “an unreviewed, self-measured product whose legal footing is disappearing for a modest and shrinking saving.” That’s a very different question than it was two years ago — and for most readers, the answer has moved toward the brand.

This page is educational and not medical advice. It does not sell, supply, or prescribe any medication, and nothing here is a dosing instruction. Legal and pricing details are current as of the lastUpdated date and change frequently; confirm specifics with a licensed US provider or pharmacy.